ITP ASH Guideline
-
Upload
seayat1103 -
Category
Health & Medicine
-
view
1.785 -
download
1
description
Transcript of ITP ASH Guideline
![Page 1: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/1.jpg)
ITP in the adultBlood.2011;117(16):4190-4207
Presentor: 周益聖Instructor: 蕭樑材
![Page 2: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/2.jpg)
Grade system of recommendation IWG definition Diagnosis Course Bleeding risk Treatment of fresh case
IVIG vs High dose MTP + prednisolone vs placebo HD dexamethasone
Treatment of refractory/relapase cases after initial steroid Splenectomy TPO agonists Rituximab
Take home massage
![Page 3: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/3.jpg)
1A, 1B, 1C, 2A, 2B, 2C Number: strength of recommendation
1-we recommend.. 2- we suggest..
Alphabetical: quality of evidence A- RCTs or exceptionally strong observation studies B- RCTs with limitation or strong observation
studies C-RCTs with serious flaws , weaker observations or indirect evidence
Blood.2011;117(16):4190-4207
![Page 4: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/4.jpg)
Newly diagnosed: diagnosis to 3 months Persistent: 3 to 12 months from diagnosis Chronic: more than 12 months
3 months12
monthsDiagnosis
Newly diagnosed Persistent Chronic
Blood. 2009;113(11):2386-2393.
![Page 5: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/5.jpg)
Recommend Check HCV and HIV (1B)
Suggest Further investigation if abnormalities other than
thrombocytopenia (including IDA) in the blood count or smear (2C)
Bone marrow examination not necessary irrespective of age with typical ITP(2C)
Insufficient evidence to recommend routine check anti-platelet Ab , APA, ANA, TPO levels
Blood.2011;117(16):4190-4207
![Page 6: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/6.jpg)
Antiphospholipid syndrome Autoimmune thrombocytopenia(eg Evans
syndrome) Common variable immune deficiency Drug administration side effect Infection with CMV, Helicobacter pylori, HCV,
HIV, varicella zoster Lymphoproliferative disorder Vaccination side effect SLE
Blood.2011;117(16):4190-4207
![Page 7: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/7.jpg)
Flow Cytometry using donor platelets as target cells detects detects autoAb in 70 %(31/44) in ITP
SPRCA ( Solid phase red cell adherence assay)for plasma anti-platelet AbSensitivity: 50% (22/44), Specificty:100% J Chin Med Assoc 2006;69(12):569-574.
![Page 8: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/8.jpg)
Suggest Treat newly diagnosed patients with platelet count
<30x10^9/L(2C) Longer courses of steroid are preferred than short
courses of steroid or IVIG as first-line treatment (2B)
IVIG combined with steroid if more rapid increase in platelet count desired(2B)
IVIG or anti-D as first line if steroid contraindicated(2C)
IVIG dose : 1g/Kg as one-time dose, repeated higher doses if necessary (2B)
Br J Haematol 1999;107(4):716-719.(1.5g/Kg)
![Page 9: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/9.jpg)
Suggest Treat newly diagnosed patients with
platelet count <30x10^9/L(2C) Longer courses of steroid are preferred than
short courses of steroid or IVIG as first-line treatment (2B)
IVIG combined with steroid if more rapid increase in platelet count desired(2B)
IVIG or anti-D as first line if steroid contraindicated(2C)
IVIG dose : 1g/Kg as one-time dose, repeated if necessary (2B) Blood.2011;117(16):4190-4207
![Page 10: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/10.jpg)
Haematologica 2006;91(8):1041-1045.
CR:>100X10^9/LPR: 30X10^9/L ~ 100X10^9/L
72 pts : steroid only ( 1mg/ kg/ day)9 pts: high dose IVIG (0.5-2g/kg)28pts: combined both5 pts: conservative
![Page 11: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/11.jpg)
Plt> 30X10^9/L:86% at 5 yearsCR:>100X10^9/L
PR: 30X10^9/L ~ 100X10^9/L
CR:61% @ 5 yrs
PR +CR:86% @ 5 yrs
Haematologica 2006;91(8):1041-1045.
![Page 12: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/12.jpg)
47.8% in aged >60 yrs @ 5 yrs
2.2% in aged <40 yrs @ 5 yrs
Fatal bleeding
76% in aged >60 years at 2 years
Plt<30x10^9/L
Non-fatal bleeding
Arch Intern Med 2000;160(11):1630-1638.
![Page 13: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/13.jpg)
Suggest Treat newly diagnosed patients with platelet
count <30x10^9/L(2C) Longer courses of steroid are preferred
than short courses of steroid or IVIG as first-line treatment (2B)
IVIG combined with steroid if more rapid increase in platelet count desired(2B)
IVIG or anti-D as first line if steroid contraindicated(2C)
IVIG dose : 1g/Kg as one-time dose, repeated if necessary (2B) Blood.2011;117(16):4190-4207
![Page 14: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/14.jpg)
IVIG 0.7g/Kg/dayD1-3
Plt<20x10^9/L
HDMP 15mg/Kg/dayD1-3Daily dose<1g
Prednisolone(10mg) 1mg/Kg/dayD4-21
Lancet 2002;359(9300):23-29.
![Page 15: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/15.jpg)
Lancet 2002;359(9300):23-29.
Longer time to loss of response
![Page 16: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/16.jpg)
Lancet 2002;359(9300):23-29.
![Page 17: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/17.jpg)
Dex40mg/dayD1-4
-Dex40mg/dayD1-4-Pred 15mg maintian
N Engl J Med 2003;349(9):831-836.
![Page 18: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/18.jpg)
-Plt at D10<90X10^9/L->70% relapse-36% required additional treatment-42% had plt >50X10^9/L at 6 months
N Engl J Med 2003;349(9):831-836.
![Page 19: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/19.jpg)
Dexamasone 40mg IVA QD x4 days Every 28 days for 6 cycles Prednisone at 0.25 mg/kg/day PO
Plt < 20X10^9 /L Bleeding symptoms related to thrombocytopenia
CR - >150X10^9/L PR - 50X10^9/L ~ 150X10^9/L MR( minimal response)
20X10^9/L ~ 50X10^9/L (Monocenter: 1996 and June 2000 at the Haematology Department of the University La Sapienza of Rome,Hospital Policlinico Umberto I Italy)
30X10^9/L ~ 50X10^9/L (GIMEMAmulticenter pilot study) NR( no response)
<20X10^9/L (Monocenter) <20X10^9/L (GIMEMAmulticenter pilot study)
Blood 2007;109(4):1401-1407.
![Page 20: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/20.jpg)
RFS
RFS according to cycles
Monocenter trial
RFS:97% at 6 months90% at 15 months58% at 50 months
RFS:Cycle 6 : 94% at 15 monthsCycle 3-4-5: 84% at 15 months
Blood 2007;109(4):1401-1407.
![Page 21: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/21.jpg)
Blood 2007;109(4):1401-1407.
![Page 22: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/22.jpg)
RFS:<18y/o: 96% at 15 ms>=18y/o: 60% at 15 ms
RFS:CR : 87% at 15msPR+MR:65% at 15ms
GIMEMAmulticenter pilot study
Blood 2007;109(4):1401-1407.
![Page 23: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/23.jpg)
Recommend Splenectomy for patients failing steroid (1B) The only treatment for sustained remission off all
treatment at 1 year and beyond in a high proportion of patients
Deferred for at least 6 months after diagnosis Blood. 2010;115(2):168-186.
Against further treatment in asymptomatic patients after splenectomy with platelet count >30x10^9/L (1C)
Blood.2011;117(16):4190-4207
![Page 24: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/24.jpg)
Br J Haematol 2003;120(6):1079-1088.
![Page 25: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/25.jpg)
Br J Haematol 2003;120(6):1079-1088.
![Page 26: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/26.jpg)
Br J Haematol 2003;120(6):1079-1088.
Truly refractory cases post splenectomy : 5/183(2.7%)
![Page 27: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/27.jpg)
Br J Haematol 2003;120(6):1079-1088.
![Page 28: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/28.jpg)
Blood 2004;104(4):956-960.
Gooup 0: spontaneous remission
Group 1: response to steroid,danazol,colchicine, vinblastin, rituximab,interferon
Group 2:response to oral cyclophosphmide, azathioprine,cyclosproine
Group 3: response to IV cyclophosphmide or C/T
![Page 29: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/29.jpg)
Blood 2004;104(4):956-960.
![Page 30: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/30.jpg)
Blood 2004;104(4):956-960.
![Page 31: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/31.jpg)
Both offer similar efficacy (1C) Blood 2004;104(9):2623-2634
Surg Endosc 2006;20(8):1208-1213.
2010 CDC recommend pneumococcal and meningococcal vaccination
for elective splenectomy One dose of H influenzae type b is not
contraindicated before splenectomy
Blood 2007;109(4):1401-1407.
![Page 32: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/32.jpg)
Recommend TPO agonists for risk of bleeding who relapse after
splenectomy or who have contraindication to splenectomy failing at least one other therapy (1B)
Suggest TPO for risk of bleeding who failed one line of
therapy (steroid or IVIG) and s/p no splenectomy (2C)
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy) (2C)
![Page 33: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/33.jpg)
Blood.2011;117(16):4190-4207
![Page 34: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/34.jpg)
Lancet 2009;373(9664):641-648.
50 mg or placebo PO once daily for 6 weeks
Increased from 50 mg to75 mg after 3 weeks in patients with platelet counts less than 50 000 per μL
![Page 35: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/35.jpg)
Lancet 2009;373(9664): 641-648.
![Page 36: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/36.jpg)
Lancet 2009;373(9664):641-648.
![Page 37: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/37.jpg)
Lancet 2008;371(9610): 395-403.
SC QW for 24 weeks
To keep Plt 50×10⁹/L to 200×10⁹/L.
Splenectomised:3ug/Kg
Non-splenectomised:2ug/Kg
![Page 38: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/38.jpg)
Lancet 2008;371(9610): 395-403.
![Page 39: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/39.jpg)
Lancet 2008;371(9610): 395-403.
![Page 40: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/40.jpg)
US FDA approval: chronic ITP with insufficient response to steroid, IVIG , or splenectomy
Thrombocytopenia recurs or worsen if suddenly abrupted
Increased risk of portal venous thrombosis in chronic liver disease
Hematol 2010;47(3):289-298.
Increased marrow reticulin fibrosis in 10/271 in the romiplostin trials
Blood 2009;114(18):3748-3756.
![Page 41: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/41.jpg)
Weekly infusion of 375mg/m2 for 4 weeks in 16/19 studies Ann Intern Med 2007;146(1):25-33.
![Page 42: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/42.jpg)
30% at one year J Support Oncol 2007;5 4 suppl 2:82-84. 2007.
9/26 (35%) had long-term response median follow-up of 57 months (range 39–69) 11/26 (42%) did not necessitate further
therapy
Eur J Haematol 2008;81(3):165-169.
![Page 43: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/43.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 44: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/44.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 45: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/45.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 46: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/46.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 47: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/47.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 48: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/48.jpg)
Treat newly diagnosed patients with platelet count <30x10^9/L
Longer courses of steroid are preferred than short courses of steroid or IVIG as first-line treatment
Splenectomy for patients failing steroid Against further treatment in asymptomatic patients
after splenectomy with platelet count >30x10^9/L TPO agonists for risk of bleeding who relpase after
splenectomy or who have contraindication to splenectomy failing at least one other therapy
Rituximab for risk of bleeding who failed one line of therapy (steroid , IVIG or splenectomy)
![Page 49: ITP ASH Guideline](https://reader034.fdocuments.net/reader034/viewer/2022051411/546616c1b4af9f623f8b5237/html5/thumbnails/49.jpg)
Thanks for your attention!